Group 1 - The Brazilian government announced an investment of 1.4 billion reais in the Butantan Institute's dengue vaccine production center to improve healthcare supplies and infrastructure for immunobiologicals [1] - The dengue vaccine produced by the Butantan Institute is 100% domestically made in Brazil and is the only single-dose vaccine approved for individuals aged 12 to 59 [1] - President Lula emphasized the importance of multilateralism and expressed Brazil's willingness to collaborate with the United States and China, highlighting China's significant role in Brazil's vaccine sector [1]

Core Viewpoint - Anxu Bio's 2025 annual performance report indicates a significant decline in revenue and profits, primarily due to increased tariffs from the U.S., rising operating costs, and foreign exchange losses [1] Financial Performance - Total operating revenue for 2025 was 453,575,110.94 yuan, a year-on-year decrease of 16.11% [1] - Operating profit was 69,056,267.09 yuan, down 66.73% year-on-year [1] - Net profit attributable to shareholders was 73,382,112.04 yuan, reflecting a 61.84% decline compared to the previous year [1] Asset and Equity Status - Total assets at the end of the reporting period were 5,612,123,002.48 yuan, a decrease of 2.72% from the end of the previous year [1] - Equity attributable to shareholders was 5,170,052,841.50 yuan, down 0.64% from the end of the previous year [1]

Group 1 - The company, Shenlian Biological (688098.SH), reported a revenue of 288.27 million yuan for the fiscal year 2025, representing a decrease of 4.99% compared to the previous year [1] - The net profit attributable to the parent company's owners was -19.09 million yuan, showing an improvement in loss reduction by 57.33% year-on-year [1]

Core Viewpoint - Kaiyin Technology (688687.SH) reported a significant decline in net profit for the year 2025, primarily due to substantial asset impairment provisions related to the withdrawal of a drug registration application [1] Financial Performance - The company achieved total operating revenue of 1.321 billion yuan, representing a year-on-year increase of 7.35% [1] - The net profit attributable to the parent company was 29.6312 million yuan, reflecting a year-on-year decrease of 79.19% [1] - The net profit attributable to the parent company after deducting non-recurring gains and losses was 22.7647 million yuan, down 83.38% year-on-year [1] Reasons for Performance Changes - The primary reason for the performance decline was the company's decision to fully provision for asset impairment related to the withdrawal of the drug registration application for Pegylated Interferon α-2 Injection (new hepatitis B indication) based on the latest review recommendations from the National Medical Products Administration [1]

Core Viewpoint - The company has received a positive review from the CHMP for its biosimilar HLX11, which is a competitor to Perjeta®, and is awaiting final approval from the European Commission [1][2]. Group 1: Regulatory Approvals - HLX11 has received a positive opinion from the CHMP, which will be submitted to the European Commission for final review in the next 2-3 months [1]. - If approved by the EC, HLX11 will be granted centralized marketing authorization across all EU member states and EEA countries [1]. - The company has also received GMP certificates from the Belgian Federal Agency for Medicines and Health Products, confirming compliance with EU GMP standards [1]. Group 2: Product Development and Market Potential - HLX11 is a biosimilar of the drug Perjeta® and was developed by the company [2]. - The company has entered into an exclusive licensing agreement with Organon LLC for the commercialization of HLX11 outside of China and Hong Kong, Macau, and Taiwan [2]. - According to IQVIA data, the global sales of Perjeta® are projected to be approximately $3.304 billion in 2024 [2].

Core Viewpoint - The company has received a positive review from the EMA's CHMP for its biosimilar HLX11, which is recommended for marketing authorization in the EU, pending final decision by the European Commission in the next 2-3 months [1] Group 1: Regulatory Approvals - HLX11's marketing authorization application (MAA) has been accepted by the EMA, and the final decision will be based on the CHMP's positive opinion [1] - The company has also received GMP certificates from the Belgian Federal Agency for Medicines and Health Products, confirming that HLX11's production lines meet EU GMP standards [1] Group 2: Product Development and Partnerships - HLX11 is a biosimilar to Perjeta (pertuzumab), and the positive review is based on data demonstrating high similarity in quality, safety, and efficacy [1] - The company has an exclusive licensing agreement with Organon LLC for the commercialization of HLX11 outside of China and Hong Kong, Macau, and Taiwan [2] - The product has received various regulatory acceptances, including NDA acceptance by the NMPA in December 2024 and BLA approval by the FDA in November 2025 [2] Group 3: Market Potential - The global sales of pertuzumab products are projected to be approximately $3.304 billion in 2024, indicating significant market potential for HLX11 as a biosimilar [2]

Core Viewpoint - Zhijiang Biotech (688317.SH) reported a significant decline in revenue and an increase in net loss for the fiscal year 2025, primarily due to pricing pressures from centralized procurement policies and changes in product sales structure [1] Financial Performance - The company achieved total operating revenue of 124.91 million yuan, a decrease of 30.08% compared to the same period last year [1] - The net profit attributable to the parent company was -34.30 million yuan, representing an increase in loss of 93.16 million yuan year-on-year [1] Factors Affecting Performance - Revenue decline was attributed to the implementation of centralized procurement policies leading to lower sales prices, an increase in the value-added tax rate on self-produced reagent products to 13%, and changes in product sales structure [1] - The decrease in financial income and reduced foreign exchange gains also contributed to the operational losses [1] Strategic Response - The company is actively responding to market competition by enhancing product research and development, exploring potential opportunities, and optimizing cost reduction and efficiency improvement measures [1] - Cost control measures have shown effectiveness, with a year-on-year reduction in asset impairment losses, leading to a decrease in operational losses compared to the previous year [1]

Core Viewpoint - The company Fuhong Hanlin (02696) has announced the completion of the first patient dosing in a Phase 2/3 clinical study of HLX22 combined with HLX87 for the first-line treatment of HER2-positive recurrent or metastatic breast cancer in mainland China [1][2] Group 1 - The clinical study is an open-label, randomized, multi-center Phase 2/3 trial evaluating the efficacy of HLX22 combined with HLX87 in patients with HER2-positive recurrent or metastatic breast cancer [2] - The study consists of two phases: the first phase is a Phase 2 trial with a 2:2:1:1 randomization ratio for treatment groups, including HLX22 combined with HLX87, and various combinations of other therapies [2] - The primary endpoint of the first phase is the objective response rate (ORR) and progression-free survival (PFS) assessed by an independent imaging review committee (BICR) [2] Group 2 - The second phase is a Phase 3 trial with a 1:1 randomization ratio comparing HLX22 combined with HLX87 to other treatment combinations [2] - The primary endpoint of the second phase is PFS evaluated by BICR [2] - The main objective of the study is to assess the clinical efficacy of HLX22 combined with HLX87, with secondary objectives including safety, tolerability, pharmacokinetics (PK), immunogenicity, and exploration of potential predictive or resistance biomarkers [2]

Core Viewpoint - The company has received a positive review opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for its biosimilar HLX11, which is a monoclonal antibody similar to Perjeta, and is awaiting final approval from the European Commission [1][2]. Group 1 - HLX11's positive review is based on data demonstrating its high similarity in quality, safety, and efficacy compared to the reference drug Perjeta, including similarity studies and pharmacokinetic studies [2]. - The company received two GMP certificates from the Belgian Federal Agency for Medicines and Health Products in June 2025, confirming that HLX11's production line meets EU GMP standards [2]. - HLX11 is a biosimilar developed by the company, with a global commercialization agreement signed with Organon LLC in June 2022, excluding China and Hong Kong, Macau, and Taiwan [3]. Group 2 - The New Drug Application (NDA) for HLX11 was accepted by the National Medical Products Administration (NMPA) in December 2024, and the Marketing Authorization Application (MAA) was accepted by the EMA in March 2025 [3]. - The New Drug Submission (NDS) for HLX11 was accepted by Health Canada in May 2025, and the Biologics License Application (BLA) was approved by the FDA in November 2025 [3]. - According to the latest data from IQVIA, the global sales of the reference drug Perjeta are projected to be approximately $3.304 billion in 2024 [3].

Core Viewpoint - The company, Junshi Biosciences (复宏汉霖), announced that its drug HLX11 has received a positive review opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP), recommending approval for its marketing authorization application [1] Group 1 - The CHMP's review opinion will be submitted to the European Commission (EC), which will consider this opinion and make a final review decision in the next 2-3 months [1] - If approved by the EC, the centralized marketing authorization for HLX11 will take effect in all EU member states and the European Economic Area (EEA) countries, including Iceland, Liechtenstein, and Norway [1]